Lung cancer patients are increasingly receiving extended chemotherapy regimens, but pulmonologist Jan Willem van den Berg warns this trend may do more harm than good. While treatment barely prolongs life, it significantly diminishes quality during the final stages.
Van den Berg and his colleagues' research shows chemotherapy offers negligible survival benefits for lung cancer patients, yet it sharply erodes end-of-life quality. Frequent hospital visits, false hopes, and less time for meaningful preparation for dying are key drawbacks he highlights.
Should chemotherapy courses be shortened for lung cancer patients to prioritize quality of life?
Source: Nu.nl | Image: Shutterstock
